Cipla Limited

Cipla Limited (CIPLA) is a large-cap Healthcare company valued at ₹1.07 lakh crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Cipla Limited last traded at ₹1,325.1, modestly down 0.22% on the day.

Recent developments

On 2026-10-04, Cipla reported record Q1FY27 revenue of ₹7,119 crore. On 2026-08-29, the Bombay High Court criticized the Maharashtra FDA for acting 'overboard' in its decision to cancel Cipla Pharma's drug licence, leading to the withdrawal of the cancellation order. On 2026-07-28, Cipla secured USFDA approval for a $908 million generic Advair Diskus opportunity, enhancing its position in the U.S. respiratory generics market.

Financial performance

The company's annual revenue rose 2.2% to ₹28,163 crore, but net profit fell 26.7% to ₹3,862 crore. In the latest quarter, revenue increased 2.3% to ₹7,119 crore, while net profit dropped 39.2% to ₹786 crore, reflecting a significant decline in profitability despite revenue growth.

Valuation multiples

The stock trades at 27.6 times earnings, broadly in line with the Healthcare median of 32.0, 3.24 times book value. It yields 0.9%.

Things to watch

The company's net profit margin fell 5.4 percentage points to 13.7%, indicating a decline in profitability. The latest quarter's net profit dropped 39.2% compared to the same quarter a year earlier, highlighting a significant challenge in maintaining profit growth. The stock is 22.2% below its 52-week high, showing a notable pullback from recent peak levels.

Where it stands

Cipla's revenue growth has slowed, with annual revenue rising 2.2% and the latest quarter up 2.3%, but net profit has declined sharply, falling 26.7% annually and 39.2% in the latest quarter. The company's net profit margin has dropped to 13.7%, and the stock is 22.2% below its 52-week high. The most significant movement is the sharp decline in net profit, reflecting ongoing challenges in profitability.

Summarised by DocStoX's model on 2026-10-10 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.